FOWLER JOHN D JR 4

4 · Emergent BioSolutions Inc. · Filed May 4, 2026

AI-generated summary of this filing

Updated May 4, 2026

Emergent BioSolutions (EBS) Director John D. Fowler Jr Receives Award

What Happened

John D. Fowler Jr., a member of the Emergent BioSolutions (EBS) board of directors, was granted two types of equity awards on April 30, 2026: 25,344 restricted stock units (RSUs) and 11,296 stock options. Both were reported as awards (Form 4 code "A") with a grant price of $0.00 (i.e., no cash paid at grant). The reported dollar value at grant is $0 on the Form 4 (these are compensatory grants, not open-market purchases).

Key Details

Transaction date: 2026-04-30 (reported on Form 4 filed 2026-05-04). Both items coded as "A" (award/grant).
RSUs: 25,344 units; each RSU converts to one share upon vesting. Stock options: 11,296 options (derivative instrument).
Vesting: Both the RSUs and the options vest on the day before the one-year anniversary of the grant (Annual Grant Vesting Date), conditional on Fowler remaining a board member through that date (see footnotes F1 and F2).
Grant economics note: The option grant size was determined using a formula that converts 25% of the non-employee director compensation value into a number of options using the Black‑Scholes option value at grant (footnote F3). The Form 4 excerpt does not list an exercise price for the options.
Shares owned after the transaction are not disclosed in the provided excerpt.
Filing timeliness: The Form 4 was filed on 2026-05-04 for the 2026-04-30 grants; this appears to be a timely filing (Form 4 is generally due within two business days).

Context

RSUs are a promise to issue shares upon vesting (no exercise required); stock options give the right to purchase shares at a set exercise price after vesting. Neither award involved an immediate cash purchase or sale of shares.
These awards are routine director compensation and do not by themselves indicate buying or selling sentiment. They do increase potential future share dilution if exercised or settled in stock.

Form 4

Period: 2026-04-30

Director

Transactions

Award
Common Stock
[F1]
2026-04-30+25,344→ 30,350 total
Award
Stock Option (Right to Buy)
[F2][F3]
2026-04-30+11,296→ 11,296 total
Exercise: $7.99Exp: 2033-04-30→ Common Stock (11,296 underlying)

Footnotes (3)

[F1]Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.
[F2]Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.
[F3]The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.

Signature

/s/ Richard S. Lindahl, Attorney-in-fact|2026-05-04

1 file